Tradestie Institutional Equity Comparison Engine

EYEG vs CBIO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CBIO Overall Edge

CBIO Captures Institutional Edge (2โ€“1 Pillars ยท 6โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Crescent Biopharma, Inc. Common Stock (CBIO) driven by superior Growth & Margin, Momentum & Technical while EYEG counters with relative strength in Options & Structure. Fundamentally, EYEG trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus CBIO at N/M Forward P/E and -1228.4% operating margin (+0.0% YoY). In options structure, EYEG sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CBIO sits in BREAKDOWN (98th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
EYEG N/M vs CBIO N/M Fwd P/E
Growth & Margin Winner CBIO
Op Margin N/A vs -1228.4% ยท YoY N/A vs +0.0%
Momentum & Technical Winner CBIO
1Y -6.4% vs -0.2% ยท 52W Pos 15% vs 23%
Options & Structure Winner EYEG
UNCLASSIFIED (N/A IV) vs BREAKDOWN (98th %ile IV)
EYEG US Equity
EYEG
Institutional Equity
$33.73
+0.48% 1D
Market Cap N/A
1M Return +0.42%
1Y Return -6.36%
Forward P/E N/M
Unified AI Score
55.0 / 100 HOLD
Tech 73.0 Fund 61.0 Flow 50.0 Mom 60.0
CBIO NASDAQ
Crescent Biopharma, Inc. Common Stock
Pharmaceutical Preparations
$13.00
+0.7% 1D
Market Cap $539.5M
1M Return -1.07%
1Y Return -0.23%
Forward P/E N/M
Unified AI Score
49.2 / 100 HOLD
Tech 45.0 Fund 56.0 Flow 67.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: EYEG -6.36% CBIO -0.23% Spread: +5.64 pp (CBIO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
EYEG TTM Op. Margin: N/A CBIO TTM Op. Margin: -1228.4%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EYEG vs CBIO. Trailing 12-month operating profitability (EYEG N/A vs CBIO -1228.4%) and valuation multiples (EYEG N/M vs CBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: EYEG (2) vs CBIO (6)
Institutional Metric EYEG CBIO Criterion Row Winner
Market Capitalization Scale N/A $539.5M Larger Scale CBIO
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A +0.0% Higher Growth CBIO
Operating Margin (TTM) Profitability N/A -1228.4% Higher Margin CBIO
Net Profit Margin Profitability N/A 0.0% Higher Margin CBIO
Return on Equity (ROE) Capital Efficiency N/A -160.8% Higher ROE CBIO
52-Week Range Position Momentum 15% ($33โ€“$36) 23% ($9โ€“$27) Stronger Trend CBIO
Beta / 30D Volatility Risk Regime 0.13ฮฒ ยท 5% Vol 1.18ฮฒ ยท 60% Vol Lower Realized Risk EYEG
Unified Institutional Score Composite Signal 55.0 / 100 (HOLD) 49.2 / 100 (HOLD) Higher Composite EYEG

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full EYEG vs CBIO Buy Guide
EYEG UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live EYEG Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CBIO BREAKDOWN
148d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 98th %ile
IV Regime Extreme (>80th %ile)
Live CBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither EYEG nor CBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.